Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
As professional antigen presenting cells (APCs) capable of eliciting primary immune responses among naïve T cells, dendritic cells (DCs) offer an attractive target for immune intervention. While some strategies for vaccination have sought to deliver antigens direct to DCs in vivo, others have pulsed...
Main Authors: | Bravo, M, Davies, TJ, Fairchild, PJ |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Bioinsights Publishing Ltd
2021
|
Similar Items
-
Integrating next-generation dendritic Cell vaccines into the current cancer immunotherapy landscape.
by: Garg, A, et al.
Published: (2017) -
iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
by: Horton, C, et al.
Published: (2019) -
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
by: Sachamitr, P, et al.
Published: (2012) -
Next‐generation Gene Silencers for Cancer Immunotherapy
by: Ng, Aik Seng
Published: (2017) -
Financial viability and technical evaluation of dendritic cell-carrying "vaccination nodes" for immunotherapy
by: Song, Andrew, M. Eng. Massachusetts Institute of Technology
Published: (2009)